Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T18:54:11.322Z Has data issue: false hasContentIssue false
  • English
  • Français

LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment

Published online by Cambridge University Press:  23 March 2020

F. Pietrini ,
M. Spadafora ,
L. Tatini ,
G.A. Talamba ,
C. Andrisano ,
G. Boncompagni ,
M. Manetti ,
V. Ricca  and
A. Ballerini
F. Pietrini*
Affiliation:
Psychiatric unit, department of neuroscience, psychology, drug research and child health, section of neuroscience, university of Florence, Via delle Gore 2HFlorence50134, Italy
M. Spadafora
Affiliation:
Psychiatric unit, department of neuroscience, psychology, drug research and child health, section of neuroscience, university of Florence, Via delle Gore 2HFlorence50134, Italy
L. Tatini
Affiliation:
Psychiatric unit, department of neuroscience, psychology, drug research and child health, section of neuroscience, university of Florence, Via delle Gore 2HFlorence50134, Italy
G.A. Talamba
Affiliation:
Psychiatric unit, department of neuroscience, psychology, drug research and child health, section of neuroscience, university of Florence, Via delle Gore 2HFlorence50134, Italy
C. Andrisano
Affiliation:
Department of biomedical and neuromotor sciences, university of Bologna, Bologna, Italy
G. Boncompagni
Affiliation:
Department of mental health and substance abuse, local health trust of Bologna, Bologna, Italy
M. Manetti
Affiliation:
Therapeutic psychiatric community, Campo del Vescovo Union, La Spezia, Italy
V. Ricca
Affiliation:
Psychiatric unit, department of neuroscience, psychology, drug research and child health, section of neuroscience, university of Florence, Via delle Gore 2HFlorence50134, Italy
A. Ballerini
Affiliation:
Psychiatric unit, department of neuroscience, psychology, drug research and child health, section of neuroscience, university of Florence, Via delle Gore 2HFlorence50134, Italy
*
* Corresponding author. Tel.: +39 055 794 7487; fax: +39 055 794 7531. E-mail address:[email protected] (F. Pietrini).
Get access

Abstract

Background

To present real-world evidence on the differences between long-acting injectable (LAI) and oral antipsychotic maintenance treatment (AMT) in terms of subjective well-being, attitudes towards drug and quality of life in a sample of remitted schizophrenic subjects.

Methods

Twenty outpatients with remitted schizophrenia treated with either olanzapine or paliperidone and switching from the oral to the LAI formulation of their maintenance treatment were recruited before the switch (LAI-AMT group). A group of 20 remitted schizophrenic subjects with oral AMT and matching main sociodemographic, clinical and treatment variables made up the control group (oral-AMT group). All participants were assessed in terms of objective (PANSS, YMRS, MADRS) and subjective (SWN-K, DAI-10, SF-36) treatment outcomes at baseline (T0) and after 6 months (T1).

Results

Between T0 and T1, general psychopathology of the PANSS, DAI-10, and all but one of the SWN-K dimensions (except for social integration), showed significantly higher percentages of improvement in the LAI-AMT group compared to the oral-AMT group. A generalized expansion of health-related quality of life, with better functioning in almost all areas of daily living, was reported by the LAI-AMT group after the 6-month period. In contrast, the oral-AMT group reported a significant worsening of health-related quality of life in the areas of emotional role and social functioning in the same period.

Conclusions

Our study indicates possible advantages of LAI over oral antipsychotic formulation in terms of subjective experience of maintenance treatment in remitted schizophrenic patients. Size and duration of this study need to be expanded in order to produce more solid and generalizable results.

Keywords

Schizophrenia and psychosisAntipsychoticsQuality of lifeQuality of care
Type
Original article
Information
European Psychiatry , Volume 37 , September 2016 , pp. 35 - 42
Copyright
Copyright © European Psychiatric Association 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Novick, DHaro, JMSuarez, DPerez, VDittmann, RWHaddad, PMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010; 176(2–3):109–113CrossRefGoogle ScholarPubMed
Higashi, KMedic, GLittlewood, KJDiez, TGranström, ODe Hert, MMedication adherence in schizophrenia: factors influencing adherence and consequences of non-adherence, a systematic literature review. Ther. Adv Psychopharmacol 2013; 3(4): 200–218CrossRefGoogle Scholar
Lehman, AFLieberman, JADixon, LBMcGlashan, THMiller, ALPerkins, DOet al.Practice guideline for the treatment of patients with schizophrenia, second edition Am J Psychiatry 2004; 161(2): 1–56Google ScholarPubMed
Carpenter, WT Jr.Hanlon, TEHeinrichs, DWSummerfelt, ATKirkpatrick, BLevine, Jet al.Continuous versus targeted medication in schizophrenic outpatients: outcome results Am J Psychiatry 1990; 147(9): 1138–1148Google ScholarPubMed
Leucht, STardy, MKomossa, KHeres, SKissling, WSalanti, Get al.Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis Lancet 2012; 379(9831): 2063–2071CrossRefGoogle ScholarPubMed
Kane, JMPharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46(10): 1396–1408CrossRefGoogle ScholarPubMed
Marder, SRSubjective experiences on antipsychotic medications: synthesis and conclusions Acta Psychiatr Scand Suppl 2005; 427:43–46CrossRefGoogle Scholar
Naber, DMoritz, SLambert, MPajonk, FGHolzbach, RMass, Ret al.Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50(1–2):79–88CrossRefGoogle ScholarPubMed
Voruganti, LCortese, LOyewumi, LCernovsky, ZZirul, SAwad, AComparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43(2–3):135–145CrossRefGoogle ScholarPubMed
Velligan, DIWang, MDiamond, PGlahn, DCCastillo, DBendle, Set al.Relationships among subjective and objective measures of adherence to oral antipsychotic medications Psychiatr Serv 2007; 58(9): 1187–1192CrossRefGoogle ScholarPubMed
Vothknecht, SSchoevers, RAde Haan, LSubjective well-being in schizophrenia as measured with the subjective well-being under neuroleptic treatment scale: a review. Aust N Z J Psychiatry 2011; 45(3): 182–192CrossRefGoogle ScholarPubMed
Lacro, JPDunn, LBDolder, CRLeckband, SGJeste, DVPrevalence of and risk factors for medication non-adherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63(10): 892–909CrossRefGoogle ScholarPubMed
Schennach-Wolff, RJäger, MObermeier, MSchmauss, MLaux, GPfeiffer, Het al.Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission? World J Biol Psychiatry 2010; 11(5): 729–738CrossRefGoogle ScholarPubMed
Kaplan, GCasoy, JZummo, JImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence 2013; 7: 1171–1180CrossRefGoogle ScholarPubMed
Barbui, CKikkert, MMazzi, MABecker, TBindman, JSchene, Aet al.Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence Psychopathology 2009; 42(5): 311–317CrossRefGoogle ScholarPubMed
Awad, AGVoruganti, LNImpact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004; 18(13): 877–893CrossRefGoogle ScholarPubMed
Haro, JMSalvador-Carulla, LThe Schizophrenia outpatient health outcome (SOHO) study: implications for the treatment of schizophrenia. CNS Drugs 2006; 20(4): 293–301CrossRefGoogle ScholarPubMed
Pietrini, FSpadafora, MTalamba, GAGodini, LLelli, LArcabasso, Set al.The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: preliminary results Int J Psychiatry Clin Pract 2015; 19(2): 106–113CrossRefGoogle Scholar
Rauch, ASFleischhacker, WWLong-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs 2013; 27(8): 637–652CrossRefGoogle ScholarPubMed
Kishimoto, TNitta, MBorenstein, MKane, JMCorrell, CULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013; 74: 957–965CrossRefGoogle ScholarPubMed
Lafeuille, MHLaliberté-Auger, FLefebvre, PFrois, CFastenau, JDuh, MSImpact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 2013; 13(1): 221CrossRefGoogle ScholarPubMed
Ju, PCChou, FHLai, TJChuang, PYLin, YJYang, CWet al.Long-acting injectables and risk for rehospitalization among patients with schizophrenia in the home care program in taiwan J Clin Psychopharmacol 2014; 34(1): 23–29CrossRefGoogle ScholarPubMed
Marinis, TDSaleem, PTGlue, PArnoldussen, WJTeijeiro, RLex, Aet al.Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia Pharmacopsychiatry 2007; 40(6): 257–263CrossRefGoogle ScholarPubMed
Lloyd, KLatif, MASimpson, SShrestha, KLSwitching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol 2010; 25(3): 243–252CrossRefGoogle ScholarPubMed
Iyer, SBanks, NRoy, MATibbo, PWilliams, RManchanda, Ret al.A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part I-patient perspectives. Can J Psychiatry 2013; 58(5 Suppl. 1):14S–22SCrossRefGoogle ScholarPubMed
Kirschner, MTheodoridou, AFusar-Poli, PKaiser, SJäger, MPatients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther. Adv Psychopharmacol 2013; 3(2): 89–99CrossRefGoogle Scholar
Rosa, FSchreiner, AThomas, PSherif, TSwitching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig 2012; 32(4): 267–279CrossRefGoogle ScholarPubMed
Niolu, CBianciardi, EDi Lorenzo, GMarchetta, CBarone, YSterbini, Net al.Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone? Ther Adv Psychopharmacol 2015; 5(5): 278–288CrossRefGoogle Scholar
Zarin, DAYoung, JLWest, JCChallenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol 2005; 40(1): 27–35CrossRefGoogle Scholar
Kane, JMKishimoto, TCorrell, CUAssessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 2013; 66(8 Suppl.):S37–S41CrossRefGoogle Scholar
Haddad, PMKishimoto, TCorrell, CUKane, JMAmbiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry 2015; 28(3): 216–221CrossRefGoogle ScholarPubMed
American psychiatric association.Diagnostic and statistical manual of mental disorders (DSM5) 5th ed.2013American Psychiatric Press Washington, DCCrossRefGoogle Scholar
Kay, SRFiszbein, AOpler, LAThe positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261–276CrossRefGoogle Scholar
Montgomery, SAAsberg, MA new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389CrossRefGoogle ScholarPubMed
Young, RCBiggs, JTZiegler, VEMeyer, DAA rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–435CrossRefGoogle ScholarPubMed
Leucht, SKane, JMKissling, WHamann, JEtschel, EEngel, RRWhat does the PANSS mean?. Schizophr Res 2005; 79(2–3):231–238CrossRefGoogle ScholarPubMed
van Os, JBurns, TCavallaro, RLeucht, SPeuskens, JHelldin, Let al.Standardized remission criteria in schizophrenia Acta Psychiatr Scand 2006; 113(2): 91–95Google Scholar
Eli Lilly and Company. ZypAdhera. Summary of product characteristics, EU. 2012.Google Scholar
Janssen-Cilag. Xeplion. Summary of product characteristics, EU. 2012.Google Scholar
Llorca, PMAbbar, MCourtet, PGuillaume, SLancrenon, SSamalin, LGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013; 13(1): 340CrossRefGoogle ScholarPubMed
First, MBSpitzer, RLGibbon, MWilliams, JBWStructured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition (SCID-I/P) New York: Biometrics Research, New York State Psychiatric Institute; 2002Google Scholar
American psychiatric association Diagnostic and statistical manual of mental disorder (DSM-IV) 4th ed. American psychiatric press Washington, DC [Text revision]Google Scholar
Nielsen, RELindström, ENielsen, JLevander, SDAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol 2012; 22(10): 747–750CrossRefGoogle Scholar
Ware, JESnow, KKosinski, MGamdek, BSF-36 health survey manual and interpretation guide Boston, MA: The Health Institute, New England Medical Center; 1997Google Scholar
Jenkinson, CCoulter, AWright, LShort form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306(6890): 1437–1440CrossRefGoogle ScholarPubMed
Fusar-Poli, PKempton, MJRosenheck, RAEfficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 2013; 28(2): 57–66CrossRefGoogle ScholarPubMed
Schrank, BBird, VTylee, ACoggins, TRashid, TSlade, MConceptualising and measuring the well-being of people with psychosis: systematic review and narrative synthesis. Soc Sci Med 2013; 92: 9–21CrossRefGoogle ScholarPubMed
Das, AKMalik, AHaddad, PMA qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther. Adv Psychopharmacol 2014; 4(5): 179–185CrossRefGoogle Scholar
Bitter, IKatona, LZámbori, JTakács, PFehér, LDiels, Jet al.Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol 2013; 23: 1383–1390CrossRefGoogle ScholarPubMed
Emsley, ROosthuizen, PKoen, LNiehaus, DJMedori, RRabinowitz, JOral versus injectable antipsychotic treatment in early psychosis: post-hoc comparison of two studies. Clin Ther 2008; 30(12): 2378–2386CrossRefGoogle ScholarPubMed
Barrio, PBatalla, ACastellví, PHidalgo, DGarcía, MOrtiz, Aet al.Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. Int Clin Psychopharmacol 2013; 28(4): 164–170Google ScholarPubMed
Dubois, VPeuskens, JGeerts, PDetraux, JClinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia treatment adherence registry (e-STAR) and trial for the Initiation and maintenance of remission in schizophrenia with risperidone (TIMORES). Early Interv Psychiatry 2014; 8(1): 39–49CrossRefGoogle Scholar
Heres, SLambert, MVauth, RTreatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 2014; 29(Suppl. 2):1409–1413CrossRefGoogle ScholarPubMed
Stahl, SMLong-acting injectable antipsychotics: shall the last be first?. CNS Spectr 2014; 19(1): 3–5CrossRefGoogle ScholarPubMed
Zhang, FSi, TChiou, CFHarris, AWKim, CYJahagirdar, Pet al.Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatr Dis Treat 2015; 11: 657–668CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.